Recursion Pharmaceuticals Q4: Why My December Buy Call Was Too Optimistic
Source: SeekingAlpha
2026-02-25 15:19:16 ET
Investment Overview
Recursion Pharmaceuticals, Inc. ( RXRX ), the self-styled "clinical-stage TechBio company with a mission to decode biology to radically improve lives" (Source: 2025 annual report/ 10-K filing ), reported its earnings earlier today, 25th February 2026. In early trading today, the stock is up >9%, priced at $3.86, and market cap valuation is precisely $2bn....
Read the full article on Seeking Alpha
For further details see:
Recursion Pharmaceuticals Q4: Why My December Buy Call Was Too Optimistic
Recursion Pharmaceuticals Inc.
NASDAQ: RXRX
RXRX Trading
0.64% G/L:
$3.15 Last:
5,777,925 Volume:
$3.215 Open:
RXRX Latest News
March 25, 2026 07:59:00 am
Recursion Announces Vicki Goodman, M.D., as Incoming Chief Medical Officer
March 21, 2026 06:45:00 am
Want $1 Million in Retirement? Invest $10,000 in These 2 AI Stocks and Hold for 10 Years.
March 05, 2026 08:30:00 am
PacBio Announces the Appointment of Chris Gibson to the Board of Directors
RXRX Stock Data
$2,001,374,702
484,488,629
1.68%
137
N/A
Biotechnology & Life Sciences
Healthcare
US
Salt Lake City
